Cidara Thera (CDTX) Stock Price, Quote & News

Company Profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enab...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 752 6170

Website: www.cidara.com

Address:

6310 Nancy Ridge Drive, Suite 101, San Diego, United States

Lord_Andrew_London Jul. 29 at 8:19 AM

$CRDF I made almost 20x last year on $CDTX that was a Company in similar situation. The were going to develop a new product to treat influenza but before they did a 20:1 R/S. Everyone yielling. It depends on what comes afterwards. Cidara was acquired by Merck for 9.2 bililion. Before R/S company value was about 50 million.

1 · Reply

SellasgpsCurativeBAT11 Jul. 25 at 4:58 AM

$SLS Part 3. Longs Have you ever seen a Nasdaq Listed late Stage Biotech Company not lined up for a single big medical conference? Sellas has over $150 Million cash on hand right now. Not even a single presentation in over 2 months. Last Investor presentation slides on the website is from February 2026. I saw the same exact actions from $CDTX Cidara Therapeutics (NASDAQ:CDTX) was acquired by Merck for $9.2 billion in an all-cash transaction. Merck paid $221.50 per share, and the acquisition closed in early January 2026. $CDTX final 10k post BO showed 6 suitors that went back and forth for over 6 months before the final deal was consummated and accepted by BO. Remember SLS doesn’t have to file any 8k until deal is accepted by BOD. Sellas independent BOD not a single open market purchase after Nov. 2025 Big JP Morgan 1x1 attended by Dr. Stergiou and CMO Cicic. Negotiations have been going on back and forth since late Nov. 2025 PPS has jumped 10 times since that. Coincidence? 😉 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jul. 15 at 6:25 PM

$SLS Baker Brothers filing was the craziest one. They never owned a single share of $CDTX but I don’t know how they squeezed in last minute. Baker Bros. Advisors completely liquidated and sold off their entire position in Cidara Therapeutics (CDTX). This final exit occurred during the early 2026 reporting period, several months after Merck announced its definitive agreement to acquire Cidara for $221.50 per share. The hedge fund officially parted ways with its 227,272 remaining shares, capitalizing on the stock's massive surge after Merck's acquisition deal. By the end of Q1, Cidara was dropped from their 13F portfolio entirely. 🤷 ✌️🙏❤️‍🩹

1 · Reply

stockforce123 Jul. 5 at 9:56 PM

$SLS Think about this, where did the rumor come from, who leaked the BO talks to the media? It was Merck in the case of $CDTX! They quietly leaked so the SP of CDTX could climb up to around $100 from $20 so their BO @$220 wouldn’t seem too ridiculous for the Merck shareholders. Same thing is happening to Sellas! BPs want $SLS to go up to at least $50 before announcing the BO @$100+ just to get their own shareholders’ approval.

1 · Reply

samsha1 Jul. 5 at 9:36 PM

$CDTX $SLS $LLY Lilly can write a check for $60 B and crown itself the “Peptide King” from diabetes, weight loss and cancer indications and will make ADC, CAR-T and mRNA outdated.

0 · Reply

samsha1 Jul. 5 at 9:17 PM

$SLS $CDTX was doubted around $10 in Oct. 2024, traded in the $40–60 range after June 25 strong data, then BO rumor pushed it toward $80–120 before the acquisition Nov 2025 for $220. A lot can happen in a year. My bull case for $SLS: • July 2025: doubted around $1.50. • 72- and 78-event updates changed the narrative. Now $14 • If GPS delivers an exceptional hazard ratio (my hope is HR <0.25) with 35+ patients remaining in durable remission, when data hits $120, THEN BO at $250.

3 · Reply

SellasgpsCurativeBAT11 Jun. 25 at 7:50 PM

$SLS $CDTX #1 Trending on Stocktwits WHY IT'S TRENDING? SELLAS Life Sciences is surging as investors interpret a recent regulatory filingwhich updates executive change-of-control agreementsas strategic preparation for a potential acquisition. This upward momentum is being further fueled by intense community discussion regarding a looming clinical catalyst and significant short-covering pressure in a stock with high borrow fees. SLS will be # 1 Biotechnology stock BO of 2026. Mark this post as I will be right here all the way to $240.00+ after the bidding war concludes. I was in $CDTX when it got BO for $221.38 WITH 6 suitors in bidding war as I posted my trade here. Merck (MSD) successfully completed a $9.2 billion acquisition of Cidara, making it a subsidiary of the pharma giant. The stock last traded near $221.38 per share. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:32 PM

$CDTX $SLS Part 3. Dr. Tsirigotis one of the lead physicians treating one of the largest trial site for Regal phase 3 said at KOL October 2025 that GPS can make Bone Marrow Transplant Obsolete head on = $3.6 Billion annually + CR1 Pre and Post BMT= $2.8 Billion + AML CR2 SOC $2.1 Billion 3 year+ maintenance $280K per year= $10 Billion+ annually before further label expansion in to 40+ other cancers = peek sale potential of $50 Billion annually by year 2030 and dethrone Keytruda as # 1 selling drug on the planet. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:22 PM

$CDTX $SLS Part 2. Dr. Angelos Stergiou TD Cowen Conference: Management explicitly targets the 13,000-patient CR1 setting via NCCN Compendium guidelines. Today, 80% of CR1 patients go untreated on "Watch and Wait" because Onureg is too toxic and transplants are too dangerous for elderly patients. An HR <0.40 forces NCCN panel action. It creates a clear mandate to recommend GPS as a simple, safe off the shelf injection. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:15 PM

$CDTX $SLS Last official Sellas PR was 34 days ago. I wouldn’t be one bit surprised if Sellas is already negotiating with multiple parties. I expect a bidding war after GPS Regal Pivotal Registrational phase 3 study. GPS has a priority voucher and orphan designation with FDA for AML CR2/CRp2. A potential suitor can have GPS off the shelf treatment on the market in record time. ✌️🙏❤️‍🩹

0 · Reply

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Nov 19, 2025, 1:05 PM EST - 9 months ago

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

MRK

Nov 17, 2025, 8:34 AM EST - 9 months ago

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

MRK

Nov 16, 2025, 6:49 PM EST - 9 months ago

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

MRK

Nov 14, 2025, 6:17 PM EST - 9 months ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

IBB MRK XBI XLV

Nov 14, 2025, 4:25 PM EST - 9 months ago

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Nov 14, 2025, 11:20 AM EST - 9 months ago

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

MRK

Nov 14, 2025, 10:00 AM EST - 9 months ago

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

MRK NVDA STUB

Nov 14, 2025, 8:30 AM EST - 9 months ago

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

MRK

Nov 14, 2025, 7:16 AM EST - 9 months ago

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

MRK

Nov 14, 2025, 6:51 AM EST - 9 months ago

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

MRK

Nov 14, 2025, 6:45 AM EST - 9 months ago

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

MRK

Nov 13, 2025, 6:53 PM EST - 9 months ago

Merck nearing deal for Cidara, FT reports

MRK

Nov 6, 2025, 4:07 PM EST - 9 months ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 9 months ago

Cidara Therapeutics to Participate in November Investor Conferences

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Oct 13, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Oct 10, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Oct 9, 2025, 8:00 AM EDT - 10 months ago

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Oct 2, 2025, 4:01 PM EDT - 10 months ago

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

Sep 25, 2025, 4:01 PM EDT - 11 months ago

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Sep 24, 2025, 7:00 AM EDT - 11 months ago

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

Sep 17, 2025, 8:00 AM EDT - 11 months ago

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Cidara Therapeutics to Participate in September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 11 months ago

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Jul 7, 2025, 1:00 PM EDT - 1 year ago

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Jul 1, 2025, 4:59 PM EDT - 1 year ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 5:15 PM EDT - 1 year ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 24, 2025, 8:00 PM EDT - 1 year ago

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Jun 23, 2025, 4:15 PM EDT - 1 year ago

Cidara Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

May 15, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

May 8, 2025, 4:15 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

PHAT

Apr 1, 2025, 4:56 PM EDT - 1 year ago

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Mar 17, 2025, 6:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

Lord_Andrew_London Jul. 29 at 8:19 AM

1 · Reply

SellasgpsCurativeBAT11 Jul. 25 at 4:58 AM

0 · Reply

SellasgpsCurativeBAT11 Jul. 15 at 6:25 PM

1 · Reply

stockforce123 Jul. 5 at 9:56 PM

1 · Reply

samsha1 Jul. 5 at 9:36 PM

$CDTX $SLS $LLY Lilly can write a check for $60 B and crown itself the “Peptide King” from diabetes, weight loss and cancer indications and will make ADC, CAR-T and mRNA outdated.

0 · Reply

samsha1 Jul. 5 at 9:17 PM

3 · Reply

SellasgpsCurativeBAT11 Jun. 25 at 7:50 PM

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:32 PM

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:22 PM

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 5:15 PM

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 4:46 PM

$CDTX $SLS I have all my shares placed for sell at LMT GTC EXT at $280.00 per share to take my emotions out of the way. I refuse to let Brokerages Borrow my shares to rescue shorts that have tried to destroy a Tiny little Biotech Co. on the cusp of a Paradigm shifting CURATIVE cancer treatment for some of the most lethal cancers on the planet. 👇 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 4:41 PM

$SLS Something definitely leaked because the desperation of big brokerage firms offering insane rates to borrow shares from my cash accounts. Last time they behaved this way was when $CDTX got bought out by Merck for $222.00 per share LAST year. Now that’s my personal experience. ✌️🙏❤️‍🩹

1 · Reply

SellasgpsCurativeBAT11 Jun. 18 at 12:28 PM

$SLS $CDTX Trading days left in June 2026 after today. Tomorrow Markets closed for Juneteenth holiday. Dr. Angelos Stergiou has yet to PR European Impact AML SLS009 enrollment PR. Brokerage calls remind me of $CDTX before BO at $222.00. Last Time Morgan Stanley was this aggressive to Borrow shares was right before Cidara take out by Merck! ✌️🙏❤️‍🩹

1 · Reply

_nic Jun. 4 at 9:03 AM

$SLS you have to be confident with what you are holding. Remember the days prior $CDTX bo annoucement. Sp went from 110 to 90 with no reason. How bad is that. Selling in this range just to see sp spiking to 150 and then 220. 💎 🤚

1 · Reply

TaylorTX May. 26 at 2:32 PM

$CRMD where’s my Cidara gang? This stock price is criminal… $CDTX

1 · Reply

De12 May. 22 at 5:33 PM

$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!

0 · Reply

BioStick123 May. 14 at 10:24 PM

$IVVD at this price, this is a layup. PEMGARDA is not the commercial story, and never was. And R&D higher should be expected with an impending Phase3. DECLARATION readout is everything, and PK data + what we know from the antibody via PEMGARDA infusion, it feels relatively de-risked. We should get a rise heading into data and data (which should be positive) could be a major re-rating driver. $CDTX on Phase data for flu antibody which was ~75% effective moved 300% from 400mcap to 1.2bn mcap. This is a larger phase 3 trial. Somewhat smaller market but vaccines for Covid are weaker efficacy / worse side effects vs Covid. Big upside potential and everything until data is just noise. Also not like they’re running out of cash. Should have $150M mid year, heading into the Q3 readout

1 · Reply

shopno Apr. 27 at 8:09 AM

$SLS Talk is cheaps, so are useless LinkedIn posts. Will Stergiou be sued and spent rest of his life in jail, in case GPS fails? NO. Cast same "NO" to his low grade greed-move with 20M RSU. $CDTX Got acquired for $9B only with early stage data, unlike $SLS which received NO buyout offer after GPS P2. CDTX raised funding AFTER the data readout, why SLS management couldn't do the same? Stergiou talks.about comprehensive P3 design, then why the f**k these idiots couldn't do statistical analysis at every IA starting at 60, 70 and then at 80th? Software analysis of a clinical trial is not damn expensive, moron! Show FU to these greedy a$$

0 · Reply

De12 Apr. 24 at 5:33 PM

$ADMA $CDTX $SWTX $VRNA $ADMA it’s Next!!

0 · Reply

SellasgpsCurativeBAT11 Apr. 23 at 10:15 PM

$SLS 👇 $CDTX Right before Buy out! ✌️🙏❤️‍🩹

0 · Reply

open_outcry Apr. 16 at 4:03 PM

$ACRV keep forgetting how low the market cap on this stock is. reminds me of $CDTX in its sub-$1 phase, and that bodes exceedingly well...

0 · Reply

De12 Apr. 14 at 11:16 PM

$ADMA Druckenmiller had buyouts with $CDTX $SWTX $VRNA and Next will be $ADMA load Up!!

2 · Reply

Market Cap	6.95B
Revenue (ttm)	1.28M
Net Income (ttm)	-169.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,267.97%
Debt to Equity Ratio	0.00

Volume	2,691,000
Avg Vol	1,496,326
Day's Range	N/A - N/A
Shares Out	31.44M
Stochastic %K	96%
Beta	1.52
Analysts	Sell
Price Target	$207.30